Highlights
Improved Oncological Outcomes
Prioritizing endoscopic submucosal dissection (ESD) for Barrett’s neoplasia larger than 15 mm increased the basal R0 resection rate from 69.7% to 91.2%.
Benefits in T1b Disease
For patients with T1b esophageal adenocarcinoma, the ESD-first strategy tripled the rate of curative resection (30.5% vs. 9.5%) and significantly reduced recurrence (23.6% vs. 55.6%).
Survival Advantage
ESD achieved a significantly higher 2-year cancer-free survival rate (87.4%) compared to endoscopic mucosal resection (EMR, 50.0%) for early esophageal cancers.
The Challenge of Large Barrett’s Neoplasia
Barrett’s esophagus (BE) remains the primary precursor to esophageal adenocarcinoma (EAC). For early-stage Barrett’s neoplasia, the goal of endoscopic therapy is to achieve a curative resection, characterized by en bloc R0 excision. Historically, Endoscopic Mucosal Resection (EMR) has been the standard of care due to its technical simplicity and widespread availability. However, EMR is limited by lesion size; for lesions larger than 15–20 mm, EMR often requires piecemeal resection, which compromises the ability of pathologists to accurately assess lateral and deep margins.
This fragmentation increases the risk of recurrence and may lead to under-staging of invasive cancers. Endoscopic Submucosal Dissection (ESD) was developed to overcome these limitations by allowing for en bloc resection regardless of lesion size. Despite its theoretical advantages, the clinical impact of universal ESD for large Barrett’s cancers has been a subject of ongoing debate, particularly regarding the balance between technical complexity and oncological benefit.
Study Design: Comparing Selective and Universal ESD Strategies
In a landmark multicenter retrospective observational study, Gupta et al. evaluated the oncological impact of two distinct resection strategies for Barrett’s cancers. The study compared a historical period (Period 1, 2004–2016), where ESD was reserved primarily for advanced or suspicious cancers, with a modern period (Period 2, 2017–2024), where an “ESD-first” strategy was prioritized for all suspected Barrett’s cancers larger than 15 mm.
The cohort included 581 resections in 542 patients, with a median lesion size of 20 mm. The researchers analyzed outcomes across 271 confirmed cancer cases, including 178 T1a and 93 T1b lesions. The primary endpoints were basal R0 resection (negative deep margin), curative resection (R0 with no high-risk features), recurrence rates, and overall safety.
Key Findings: The Superiority of the ESD-First Approach
The shift toward a universal ESD strategy in Period 2 resulted in a dramatic increase in ESD utilization, rising from 21.2% in the historical cohort to 77.1% in the modern cohort. This transition was accompanied by a significant improvement in oncological markers.
R0 Resection Rates
The overall basal R0 resection rate improved significantly from 69.7% in Period 1 to 91.2% in Period 2 (p < 0.001). This metric is critical because a positive basal margin in an endoscopic specimen often necessitates radical surgery (esophagectomy), even if the lesion was theoretically curable.
Recurrence and Survival
One of the most striking findings was the impact on cancer recurrence. By achieving en bloc resection more consistently, the ESD-first strategy led to lower recurrence rates. Furthermore, when comparing the techniques directly, ESD was associated with a 2-year cancer-free survival rate of 87.4%, whereas EMR lagged significantly at 50.0% (p = 0.021).
The Impact on T1b Cancers: A Significant Clinical Shift
While T1a cancers (limited to the mucosa) are generally considered highly curable by any endoscopic means, T1b cancers (invading the submucosa) present a greater challenge. The study demonstrated that the ESD-first strategy was particularly transformative for these higher-risk lesions.
For T1b cancers, the basal R0 resection rate jumped from 33.3% in the EMR-heavy Period 1 to 81.9% in the ESD-first Period 2. This improvement allowed for a much higher rate of curative resections (30.5% vs. 9.5%), potentially sparing many patients from the morbidity of an esophagectomy. Recurrence for T1b lesions was also slashed from 55.6% to 23.6%.
Safety and Technical Considerations
A common concern regarding the adoption of ESD is the perceived increase in adverse events, such as perforation or stricture formation, compared to EMR. However, this study found that adverse events were infrequent (2.2%) and did not differ significantly between the two periods or techniques. This suggests that in expert hands, ESD is as safe as EMR while providing superior oncological outcomes.
Expert Commentary: Why R0 Resection is Non-Negotiable
The findings by Gupta et al. reinforce a growing consensus in interventional endoscopy: for suspected malignancy, the quality of the first resection is paramount. Piecemeal EMR for a cancer >15 mm is essentially a diagnostic compromise that may sacrifice the patient’s best chance at a curative endoscopic outcome.
Experts note that the accurate histological staging provided by an en bloc ESD specimen is invaluable. For T1b cancers, knowing the exact depth of invasion (in microns) and the presence or absence of lymphovascular invasion allows for precise risk stratification. Without an R0 resection, clinicians are often left in a “grey zone,” unsure if a positive margin represents residual disease or simply an artifact of a fragmented resection.
While ESD requires a steeper learning curve and longer procedure times, the data suggests that these costs are justified by the reduction in recurrences and the improvement in cancer-free survival. The “ESD-first” approach for lesions >15 mm should now be considered the benchmark for tertiary referral centers.
Conclusion: Implementing ESD in Routine Practice
The study concludes that prioritizing ESD for Barrett’s cancers larger than 15 mm significantly improves basal R0 resection rates, reduces recurrence, and enhances short-term survival, especially for T1b disease. These results support the routine use of ESD for all larger Barrett’s cancers where malignancy is suspected.
For clinical practice, this implies that endoscopists should have a low threshold for referring large or suspicious Barrett’s lesions to centers with high-volume ESD expertise. Ensuring an en bloc R0 resection at the first attempt is the most effective strategy for optimizing long-term patient outcomes in early esophageal adenocarcinoma.
References
Gupta S, Bucalau AM, Mandarino FV, et al. Oncological impact of universal endoscopic submucosal dissection for large Barrett’s cancers. Gut. 2026;75(4):725-732. PMID: 41545198.
